Signaturefd LLC Buys 1,262 Shares of GSK plc (NYSE:GSK)

Signaturefd LLC grew its stake in GSK plc (NYSE:GSK) by 4.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,913 shares of the pharmaceutical company’s stock after acquiring an additional 1,262 shares during the quarter. Signaturefd LLC’s holdings in GSK were worth $1,109,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. FinTrust Capital Advisors LLC boosted its stake in GSK by 6.9% in the 3rd quarter. FinTrust Capital Advisors LLC now owns 4,346 shares of the pharmaceutical company’s stock worth $158,000 after purchasing an additional 281 shares in the last quarter. UMB Bank n.a. raised its holdings in GSK by 4.8% in the 3rd quarter. UMB Bank n.a. now owns 6,462 shares of the pharmaceutical company’s stock worth $234,000 after acquiring an additional 297 shares during the last quarter. KCS Wealth Advisory lifted its position in GSK by 1.5% in the 3rd quarter. KCS Wealth Advisory now owns 21,391 shares of the pharmaceutical company’s stock valued at $775,000 after acquiring an additional 314 shares in the last quarter. Caprock Group LLC boosted its stake in GSK by 2.8% during the 4th quarter. Caprock Group LLC now owns 11,513 shares of the pharmaceutical company’s stock valued at $430,000 after purchasing an additional 317 shares during the last quarter. Finally, Horizon Bancorp Inc. IN increased its holdings in shares of GSK by 8.9% in the 4th quarter. Horizon Bancorp Inc. IN now owns 3,961 shares of the pharmaceutical company’s stock worth $147,000 after purchasing an additional 323 shares in the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Trading Up 2.1 %

GSK stock opened at $40.60 on Tuesday. GSK plc has a 52-week low of $33.33 and a 52-week high of $43.84. The company has a market cap of $84.14 billion, a P/E ratio of 13.49, a P/E/G ratio of 1.40 and a beta of 0.64. The company has a quick ratio of 0.62, a current ratio of 0.88 and a debt-to-equity ratio of 1.19. The business has a 50-day simple moving average of $41.88 and a two-hundred day simple moving average of $38.86.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.04). GSK had a net margin of 16.24% and a return on equity of 51.45%. The business had revenue of $10 billion for the quarter, compared to the consensus estimate of $9.79 billion. Analysts predict that GSK plc will post 4.03 EPS for the current year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, April 11th. Investors of record on Friday, February 23rd were issued a $0.3564 dividend. This is a boost from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 dividend on an annualized basis and a yield of 3.51%. The ex-dividend date was Thursday, February 22nd. GSK’s dividend payout ratio (DPR) is currently 52.82%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on GSK shares. Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. Citigroup raised shares of GSK from a “neutral” rating to a “buy” rating in a report on Tuesday, February 13th. Jefferies Financial Group raised shares of GSK from a “hold” rating to a “buy” rating in a report on Wednesday, January 3rd. Finally, Morgan Stanley assumed coverage on shares of GSK in a report on Tuesday, January 23rd. They issued an “equal weight” rating on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.